Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD

Mark A Bellgrove, Edwina Barry, Katherine A Johnson, Marie Cox, Aoife Daibhis, Michael Daly, Ziarih Hawi, David Lambert, Michael Fitzgerald, Fiona McNicholas, Ian H Robertson, Michael Gill, Aiveen Kirley

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a heritable childhood onset disorder that is marked by variability at multiple levels including clinical presentation, cognitive profile, and response to stimulant medications. It has been suggested that this variability may reflect etiological differences, particularly, at the level of underlying genetics. This study examined whether an attentional phenotype-spatial attentional bias could serve as a marker of symptom severity, genetic risk, and stimulant response in ADHD. A total of 96 children and adolescents with ADHD were assessed on the Landmark Task, which is a sensitive measure of spatial attentional bias. All children were genotyped for polymorphisms (3' untranslated (UTR) and intron 8 variable number of tandem repeats (VNTRs)) of the dopamine transporter gene (DAT1). Spatial attentional bias correlated with ADHD symptom levels and varied according to DAT1 genotype. Children who were homozygous for the 10-repeat allele of the DAT1 3'-UTR VNTR displayed a rightward attentional bias and had higher symptom levels compared to those with the low-risk genotype. A total of 26 of these children who were medication naive performed the Landmark Task at baseline and then again after 6 weeks of stimulant medication. Left-sided inattention (rightward bias) at baseline was associated with an enhanced response to stimulants at 6 weeks. Moreover, changes in spatial bias with stimulant medications, varied as a function of DAT1 genotype. This study suggests an attentional phenotype that relates to symptom severity and genetic risk for ADHD, and may have utility in predicting stimulant response in ADHD.

Original languageEnglish
Pages (from-to)2536-2545
Number of pages10
JournalNeuropsychopharmacology
Volume33
Issue number10
Early online date28 Nov 2007
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Attention Deficit Disorder with Hyperactivity
Genetic Markers
Minisatellite Repeats
Genotype
Phenotype
Dopamine Plasma Membrane Transport Proteins
Introns
Attentional Bias
Alleles
Genes

Keywords

  • ADHD
  • attention
  • dopamine
  • genetics
  • stimulants
  • DAT1

Cite this

Bellgrove, M. A., Barry, E., Johnson, K. A., Cox, M., Daibhis, A., Daly, M., ... Kirley, A. (2008). Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD. Neuropsychopharmacology, 33(10), 2536-2545. https://doi.org/10.1038/sj.npp.1301637

Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD. / Bellgrove, Mark A ; Barry, Edwina; Johnson, Katherine A ; Cox, Marie; Daibhis, Aoife; Daly, Michael; Hawi, Ziarih; Lambert, David; Fitzgerald, Michael; McNicholas, Fiona; Robertson, Ian H; Gill, Michael; Kirley, Aiveen.

In: Neuropsychopharmacology, Vol. 33, No. 10, 09.2008, p. 2536-2545.

Research output: Contribution to journalArticle

Bellgrove, MA, Barry, E, Johnson, KA, Cox, M, Daibhis, A, Daly, M, Hawi, Z, Lambert, D, Fitzgerald, M, McNicholas, F, Robertson, IH, Gill, M & Kirley, A 2008, 'Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD', Neuropsychopharmacology, vol. 33, no. 10, pp. 2536-2545. https://doi.org/10.1038/sj.npp.1301637
Bellgrove, Mark A ; Barry, Edwina ; Johnson, Katherine A ; Cox, Marie ; Daibhis, Aoife ; Daly, Michael ; Hawi, Ziarih ; Lambert, David ; Fitzgerald, Michael ; McNicholas, Fiona ; Robertson, Ian H ; Gill, Michael ; Kirley, Aiveen. / Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD. In: Neuropsychopharmacology. 2008 ; Vol. 33, No. 10. pp. 2536-2545.
@article{2344db777bd44fcdb64018eb5acf38c7,
title = "Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD",
abstract = "Attention-deficit hyperactivity disorder (ADHD) is a heritable childhood onset disorder that is marked by variability at multiple levels including clinical presentation, cognitive profile, and response to stimulant medications. It has been suggested that this variability may reflect etiological differences, particularly, at the level of underlying genetics. This study examined whether an attentional phenotype-spatial attentional bias could serve as a marker of symptom severity, genetic risk, and stimulant response in ADHD. A total of 96 children and adolescents with ADHD were assessed on the Landmark Task, which is a sensitive measure of spatial attentional bias. All children were genotyped for polymorphisms (3' untranslated (UTR) and intron 8 variable number of tandem repeats (VNTRs)) of the dopamine transporter gene (DAT1). Spatial attentional bias correlated with ADHD symptom levels and varied according to DAT1 genotype. Children who were homozygous for the 10-repeat allele of the DAT1 3'-UTR VNTR displayed a rightward attentional bias and had higher symptom levels compared to those with the low-risk genotype. A total of 26 of these children who were medication naive performed the Landmark Task at baseline and then again after 6 weeks of stimulant medication. Left-sided inattention (rightward bias) at baseline was associated with an enhanced response to stimulants at 6 weeks. Moreover, changes in spatial bias with stimulant medications, varied as a function of DAT1 genotype. This study suggests an attentional phenotype that relates to symptom severity and genetic risk for ADHD, and may have utility in predicting stimulant response in ADHD.",
keywords = "ADHD, attention, dopamine, genetics, stimulants, DAT1",
author = "Bellgrove, {Mark A} and Edwina Barry and Johnson, {Katherine A} and Marie Cox and Aoife Daibhis and Michael Daly and Ziarih Hawi and David Lambert and Michael Fitzgerald and Fiona McNicholas and Robertson, {Ian H} and Michael Gill and Aiveen Kirley",
year = "2008",
month = "9",
doi = "10.1038/sj.npp.1301637",
language = "English",
volume = "33",
pages = "2536--2545",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Spatial attentional bias as a marker of genetic risk, symptom severity and stimulant response in ADHD

AU - Bellgrove, Mark A

AU - Barry, Edwina

AU - Johnson, Katherine A

AU - Cox, Marie

AU - Daibhis, Aoife

AU - Daly, Michael

AU - Hawi, Ziarih

AU - Lambert, David

AU - Fitzgerald, Michael

AU - McNicholas, Fiona

AU - Robertson, Ian H

AU - Gill, Michael

AU - Kirley, Aiveen

PY - 2008/9

Y1 - 2008/9

N2 - Attention-deficit hyperactivity disorder (ADHD) is a heritable childhood onset disorder that is marked by variability at multiple levels including clinical presentation, cognitive profile, and response to stimulant medications. It has been suggested that this variability may reflect etiological differences, particularly, at the level of underlying genetics. This study examined whether an attentional phenotype-spatial attentional bias could serve as a marker of symptom severity, genetic risk, and stimulant response in ADHD. A total of 96 children and adolescents with ADHD were assessed on the Landmark Task, which is a sensitive measure of spatial attentional bias. All children were genotyped for polymorphisms (3' untranslated (UTR) and intron 8 variable number of tandem repeats (VNTRs)) of the dopamine transporter gene (DAT1). Spatial attentional bias correlated with ADHD symptom levels and varied according to DAT1 genotype. Children who were homozygous for the 10-repeat allele of the DAT1 3'-UTR VNTR displayed a rightward attentional bias and had higher symptom levels compared to those with the low-risk genotype. A total of 26 of these children who were medication naive performed the Landmark Task at baseline and then again after 6 weeks of stimulant medication. Left-sided inattention (rightward bias) at baseline was associated with an enhanced response to stimulants at 6 weeks. Moreover, changes in spatial bias with stimulant medications, varied as a function of DAT1 genotype. This study suggests an attentional phenotype that relates to symptom severity and genetic risk for ADHD, and may have utility in predicting stimulant response in ADHD.

AB - Attention-deficit hyperactivity disorder (ADHD) is a heritable childhood onset disorder that is marked by variability at multiple levels including clinical presentation, cognitive profile, and response to stimulant medications. It has been suggested that this variability may reflect etiological differences, particularly, at the level of underlying genetics. This study examined whether an attentional phenotype-spatial attentional bias could serve as a marker of symptom severity, genetic risk, and stimulant response in ADHD. A total of 96 children and adolescents with ADHD were assessed on the Landmark Task, which is a sensitive measure of spatial attentional bias. All children were genotyped for polymorphisms (3' untranslated (UTR) and intron 8 variable number of tandem repeats (VNTRs)) of the dopamine transporter gene (DAT1). Spatial attentional bias correlated with ADHD symptom levels and varied according to DAT1 genotype. Children who were homozygous for the 10-repeat allele of the DAT1 3'-UTR VNTR displayed a rightward attentional bias and had higher symptom levels compared to those with the low-risk genotype. A total of 26 of these children who were medication naive performed the Landmark Task at baseline and then again after 6 weeks of stimulant medication. Left-sided inattention (rightward bias) at baseline was associated with an enhanced response to stimulants at 6 weeks. Moreover, changes in spatial bias with stimulant medications, varied as a function of DAT1 genotype. This study suggests an attentional phenotype that relates to symptom severity and genetic risk for ADHD, and may have utility in predicting stimulant response in ADHD.

KW - ADHD

KW - attention

KW - dopamine

KW - genetics

KW - stimulants

KW - DAT1

U2 - 10.1038/sj.npp.1301637

DO - 10.1038/sj.npp.1301637

M3 - Article

VL - 33

SP - 2536

EP - 2545

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 10

ER -